Comparative Pharmacology
Head-to-head clinical analysis: IOSAT versus THYRO BLOCK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOSAT versus THYRO BLOCK.
IOSAT vs THYRO-BLOCK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks thyroidal uptake of radioactive iodine isotopes, reduces thyroid exposure to radiation by saturating thyroid gland with stable iodine.
THYRO-BLOCK (potassium iodide) inhibits thyroid hormone synthesis and release by blocking the oxidation of iodide to iodine, thereby preventing the incorporation of iodine into thyroglobulin. It also reduces the vascularity of the thyroid gland.
Adults: 130 mg orally once daily for potassium iodide (SSKI 1 g/mL). For thyroid protection in radiation exposure: 130 mg orally once, may repeat after 24 hours if necessary.
Oral, 120 mg every 12 hours (total daily dose 240 mg) starting 24 hours before exposure to radioactive iodine and continuing for 5–10 days as directed.
None Documented
None Documented
3-5 days in euthyroid individuals; prolonged in hyperthyroidism (6-12 days) and renal impairment (up to 30 days)
Terminal elimination half-life is approximately 36 hours (range 24-48 hours) in euthyroid patients; prolonged in hyperthyroid patients due to increased thyroid hormone binding and reduced clearance.
Renal: >99% as iodide; fecal/biliary: <1%
Primarily renal excretion of unchanged drug (80-90% of absorbed dose) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category C
Antithyroid Agent
Antithyroid Agent